Most importantly, however, when all three drugs were tested on MUC16-positive ovarian cancer cells, Meso64-TR3 was capable of eradicating nearly all target cells (92%), followed by Meso-TR3 (59%) and TR3 (14%) (Figure 2C). This evidence concerns the gene MUC16 and ovarian cancer.